Myricx Bio licenses Wuxi antibody for ADC with NMTi-based payload
Nov. 22, 2023
Myricx Bio (Myricx Pharma Ltd.) and Wuxi Biologics Co. Ltd. have entered into a license agreement under which Myricx will have exclusive access to a proprietary antibody that was discovered based on Wuxi Bio's integrated technology platforms.